retatrutide fda approval status november 2025 Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and GLP-1 Pipeline Update: August 2025

through the combination of sulfydryl and free radicals in vivo, the free radicals can be directly reduced and converted into easily metabolized acid substances, so that the excretion of the free radicals is accelerated, and the damage of the free radicals to important organs can be resisted

None of these is necessarily permanent

A doctor can determine whether to slow titration, hold a dose, reduce the dose, change supportive care, check labs, or reassess whether the medication is appropriate

Side Effects Comparison Both medications can cause nausea, vomiting, diarrhea, and stomach discomfort, especially when starting

The study was conducted in accordance with the local legislation and institutional requirements

Head-to-head data from the SURMOUNT trials showed tirzepatide producing slightly greater weight loss at equivalent treatment durations